2022 Impact Factor
2.3

EDITORS IN CHIEF
M. B. Bilò (Italy)
P. Carreiro-Martins (Portugal)

DEPUTY EDITORS

R. Rodrigues Alves (Portugal)
D. Villalta (Italy)

ASSOCIATE EDITORS

R. Asero (Italy)
M. Branco Ferreira (Portugal)

L. Cecchi (Italy)
E. Scala (Italy)
D. Solé (Brasil)
G. Sturm (Austria)

EDITORIAL BOARD
I. Agache (Romania)
I. Annesi Maesano (France)
L. Antonicelli (Italy)
G. Azizi (Iran)
L.M. Borrego (Portugal)
K. Brockow (Germany)
S. Bavbek (Turkey)
E. Cichocka-Jarosz (Poland)
M. Cugno (Italy)
L. Delgado (Portugal)
P. Demoly (France)
G. D'Amato (Italy)
S. Durham (UK)
M. Faber (Belgium)
M. Fernandez-Rivas (Spain)
J. Fonseca (Portugal)
ZS. Gao (China)
G.P. Girolomoni (Italy)
E. Goudouris (Brasil)
A. Grumach (Brasil)
G. Kostantinou (Greece)
F. Levi-Shaffer (Israel)
M. Maurer (Germany)
L. Mayorga (Spain)
C. Micheletto (Italy)
M. Morais de Almeida (Portugal)
G. Moscato (Italy)
A. Musarra (Italy)
C. Nunes (Portugal)
M. Ollert (Lussemburgo)
P. Parronchi (Italy)
G. Passalacqua (Italy)
E. Pedro (Portugal)
A. Perino (Italy)
O. Quercia (Italy)
A. Romano (Italy)
G. Scadding (UK)
A. Todo Bom (Portugal)
A. Tedeschi (Italy)
R. van Ree (Netherland)
S. Voltolini (Italy)

FOUNDERS

F. Bonifazi (Italy)
A. Sabbah (France)

*************************

Chief Executive Officer
Ludovico Baldessin

Editorial Coordinator
Barbara Moret

Publishing Editor
Jessica Guenzi
j.guenzi@lswr.it

Sales

dircom@lswr.it

EDRA SpA
Via G. Spadolini, 7

20141 Milano - Italy
Ph. 0039 (0)2-88184.1
Fax 0039 (0)2-88184.301
www.edraspa.it

Follow us on LinkedIn

Table of Contents »

Asthma and COVID-19 pandemic: focus on the eosinophil count and ACE2 expression

Z. Kanannejad¹, S. Alyasin alyasins@sums.ac.ir^1,2, H. Esmaeilzadeh esmailzadeh_ho@yahoo.com^1,2, H. Nabavizadeh^1,2, R. Amin^1,2

Show more: Authors information and Publication history

Doi
10.23822/EurAnnACI.1764-1489.233

Summary
Currently, the world is engaged with a coronavirus disease 2019 (COVID-19) caused by acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection. The Center for Disease Control and Prevention (CDC) has proposed moderate to severe asthma as a risk factor for COVID-19 susceptibility and severity. However, current evidences have not identified asthma in the top 10 comorbidities associated with COVID-19 fatalities. It raises the question that why patients with different type of asthma are not more vulnerable to SARS-CoV-2 infection like other respiratory infection. Increased number of eosinophils and elevated angiotensin-converting enzyme 2 (ACE2) expressions in asthma are supposed as two mechanisms which associated with decreased COVID-19 susceptibility in asthmatics. Some studies have been performed to evaluate two mentioned factors in asthmatic patients compared with healthy individuals. Herein, we address these mechanisms and investigate whether ACE2 and eosinophil could protect asthmatic patients against SARS-CoV-2 infection.

Key words
Asthma; SARS-CoV-2; COVID-19; ACE2; eosinophil.

Cite this article as:
Kanannejad Z, Alyasin S, Esmaeilzadeh H, Nabavizadeh H, Amin R. Asthma and COVID-19 pandemic: focus on the eosinophil count and ACE2 expression. Eur Ann Allergy Clin Immunol. 2022;54(6):284-289. doi: 10.23822/EurAnnACI.1764-1489.233.

FULL TEXT